270 related articles for article (PubMed ID: 26506885)
41. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
42. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights.
Mas L; Lupinacci RM; Cros J; Bachet JB; Coulet F; Svrcek M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201897
[TBL] [Abstract][Full Text] [Related]
43. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
[TBL] [Abstract][Full Text] [Related]
44. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts.
Kanda M; Knight S; Topazian M; Syngal S; Farrell J; Lee J; Kamel I; Lennon AM; Borges M; Young A; Fujiwara S; Seike J; Eshleman J; Hruban RH; Canto MI; Goggins M
Gut; 2013 Jul; 62(7):1024-33. PubMed ID: 22859495
[TBL] [Abstract][Full Text] [Related]
45. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.
Wu J; Matthaei H; Maitra A; Dal Molin M; Wood LD; Eshleman JR; Goggins M; Canto MI; Schulick RD; Edil BH; Wolfgang CL; Klein AP; Diaz LA; Allen PJ; Schmidt CM; Kinzler KW; Papadopoulos N; Hruban RH; Vogelstein B
Sci Transl Med; 2011 Jul; 3(92):92ra66. PubMed ID: 21775669
[TBL] [Abstract][Full Text] [Related]
46. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
47. Lessons from McCune-Albright syndrome-associated intraductal papillary mucinous neoplasms: : GNAS-activating mutations in pancreatic carcinogenesis.
Parvanescu A; Cros J; Ronot M; Hentic O; Grybek V; Couvelard A; Levy P; Chanson P; Ruszniewski P; Sauvanet A; Gaujoux S
JAMA Surg; 2014 Aug; 149(8):858-62. PubMed ID: 24898823
[TBL] [Abstract][Full Text] [Related]
48. Invasive ductal adenocarcinoma of the remnant pancreatic body 9 years after resection of an intraductal papillary-mucinous carcinoma of the pancreatic head: a case report and comparison of DNA sequence in K-ras gene mutation.
Komori T; Ishikawa O; Ohigashi H; Yamada T; Sasaki Y; Imaoka S; Nakaizumi A; Uehara H; Tanaka S; Mano Y; Kasugai T
Jpn J Clin Oncol; 2002 Apr; 32(4):146-51. PubMed ID: 12072425
[TBL] [Abstract][Full Text] [Related]
49. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
[TBL] [Abstract][Full Text] [Related]
50. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
51. Intraductal oncocytic papillary neoplasm of the pancreas: report of a case requiring completion pancreatectomy.
Wohlauer MV; McManus M; Fukami N; Gajdos C
JOP; 2013 Jan; 14(1):77-80. PubMed ID: 23306340
[TBL] [Abstract][Full Text] [Related]
52. [Intraductal papillary mucinous neoplasms of the pancreas: pro surgical therapy--pro surveillance].
Uhl W; Belyaev O; Herzog T; Mueller CA; Seelig M; Schmidt W; Hohenberger W; Ellenrieder V
Z Gastroenterol; 2008 Nov; 46(11):1290-7. PubMed ID: 19012202
[TBL] [Abstract][Full Text] [Related]
53. The distance of tumor spread in the main pancreatic duct of an intraductal papillary-mucinous neoplasm: where to resect and how to predict it.
Okada K; Imaizumi T; Hirabayashi K; Matsuyama M; Yazawa N; Dowaki S; Tobita K; Ohtani Y; Kawaguchi Y; Tanaka M; Inokuchi S; Makuuchi H
J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):516-22. PubMed ID: 20714841
[TBL] [Abstract][Full Text] [Related]
54. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
[TBL] [Abstract][Full Text] [Related]
55. GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype.
Hata T; Mizuma M; Motoi F; Omori Y; Ishida M; Nakagawa K; Hayashi H; Morikawa T; Kamei T; Furukawa T; Unno M
Sci Rep; 2020 Oct; 10(1):17761. PubMed ID: 33082481
[TBL] [Abstract][Full Text] [Related]
56. Intraductal Papillary Neoplasm of Bile Duct: Updated Clinicopathological Characteristics and Molecular and Genetic Alterations.
Nakanuma Y; Uesaka K; Kakuda Y; Sugino T; Kubota K; Furukawa T; Fukumura Y; Isayama H; Terada T
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33317146
[TBL] [Abstract][Full Text] [Related]
57. Familial Intraductal Papillary Mucinous Neoplasm Associated With the Germline MSH6 Missense Variant and Progression of Pancreatic cancer.
Tezuka K; Yamakawa M; Murakami R; Hirai I; Toya R; Suzuki A; Kawamura H; Miyano Y; Sato H; Motoi F
Pancreas; 2024 Jul; 53(6):e476-e486. PubMed ID: 38416847
[TBL] [Abstract][Full Text] [Related]
58. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.
Basturk O; Tan M; Bhanot U; Allen P; Adsay V; Scott SN; Shah R; Berger MF; Askan G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Sigel C; Iacobuzio-Donahue C; Klimstra DS
Mod Pathol; 2016 Sep; 29(9):1058-69. PubMed ID: 27282351
[TBL] [Abstract][Full Text] [Related]
59. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
60. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes.
Komatsu H; Tanji E; Sakata N; Aoki T; Motoi F; Naitoh T; Katayose Y; Egawa S; Unno M; Furukawa T
PLoS One; 2014; 9(2):e87875. PubMed ID: 24498386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
